Drug Profile
Research programme: transdermal vaccines - Merck/Vaxxas
Alternative Names: HD-MAP vaccine - Merck/Vaxxas; Nanopatch™ vaccines - Merck/VaxxasLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Merck & Co; Vaxxas
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Unspecified(Prevention) in USA (Transdermal, Patch)
- 09 Apr 2021 Vaxxas has patents pending worldwide for differential coating of microprojections and microneedles on arrays
- 28 May 2020 Preclinical development is ongoing in USA